alexa Are Fragment C Gamma Receptor (FCGR) Germline Polymorphisms Predictive Biomarkers in Metastatic Colorectal Cancer?
ISSN: 2157-7412

Journal of Genetic Syndromes & Gene Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Are Fragment C Gamma Receptor (FCGR) Germline Polymorphisms Predictive Biomarkers in Metastatic Colorectal Cancer?

Formica V*, Cereda V, Nardecchia A, Morelli C, Lucchetti J and Roselli M

Medical Oncology Unit, ‘Tor Vergata’ Clincal Center, University of Rome, Italy

*Corresponding Author:
Vincenzo Formica, MD
Medical Oncology Unit
‘Tor Vergata’ Clincal Center University of Rome
Viale Oxford, 81 00133 Rome, Italy
Tel: +390620908190
Fax: +390620903804
E-mail: [email protected]

Received date: September 03, 2013; Accepted date:October 15, 2013; Published date: October 25, 2013

Citation: Formica V, Cereda V, Nardecchia A, Morelli C, Lucchetti J, et al. (2013) Are Fragment C Gamma Receptor (FCGR) Germline Polymorphisms Predictive Biomarkers in Metastatic Colorectal Cancer? J Genet Syndr Gene Ther 4:193. doi:10.4172/2157-7412.1000193

Copyright: © 2013 Formica V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



The treatment of metastatic colorectal cancer has undergone significant improvements over the last decade with the introduction of molecularly targeted monoclonal antibodies (mAbs). Among these, cetuximab, a chimeric IgG1 antibody directed against the extracellular domain of EGFR, has demonstrated a survival benefit for KRAS wild type (WT) tumors. Even though KRAS genotyping has significantly refined patient selection allowing an increase in tumor radiological response from 25% of the whole metastatic colorectal cancer (MCRC) population to 45% of the KRAS-WT subset, still for a significant proportion of patients anti-EGFR mAbs will be ineffective, thus resulting in unnecessary toxicity and cost.

Polymorphisms of Fragment C gamma receptor (FCGR) gene have the potential for being used as predictive biomarkers of cetuximab activity since part of this drug’s tumoricidal effect is immune-mediated via FcγR-triggered ADCC (antibody-dependent cellular cytotoxicity). The aim of the present review is to summarize available data on the predictive/prognostic value of FCGR polymorphisms for cetuximab-treated MCRC patients and to discuss possible future directions in this area of research.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version